You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthylmorphine
Accession NumberDB01466
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).
Structure
Thumb
Synonyms
Dionine
Ethyl morphine
Ethylmorphine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CodethylineErfa
DioninaMerck
LephetonMeda
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIRWO67D87EU
CAS number76-58-4
WeightAverage: 313.3908
Monoisotopic: 313.167793607
Chemical FormulaC19H23NO3
InChI KeyInChIKey=OGDVEMNWJVYAJL-LEPYJNQMSA-N
InChI
InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-10-ethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraen-14-ol
SMILES
[H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationEthylmorphine is an analgesic used for pain relief.
PharmacodynamicsEthylmorphine is metabolized by the enzyme cytochrome P450 2D6 to morphine. Morphine is a narcotic pain management agent indicated for the relief of pain in patients who require opioid analgesics for more than a few days. Morphine interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, morphine exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Morphine appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.
Mechanism of actionEthylmorphine is metabolized by the liver enzyme cytochrome P450 2D6 to morphine. The precise mechanism of the analgesic action of morphine is unknown. However, specific CNS opiate receptors have been identified and likely play a role in the expression of analgesic effects. Morphine first acts on the mu-opioid receptors. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation. It has been shown that morphine binds to and inhibits GABA inhibitory interneurons. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

After ingestion, ethylmorphine is converted to morphine in the human liver by the CYP450-isozyme CYP2D6, similarly to codeine.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ethylmorphine Action PathwayDrug actionSMP00681
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9981
Caco-2 permeable+0.7931
P-glycoprotein substrateSubstrate0.8987
P-glycoprotein inhibitor IInhibitor0.682
P-glycoprotein inhibitor IINon-inhibitor0.6396
Renal organic cation transporterInhibitor0.6561
CYP450 2C9 substrateNon-substrate0.8039
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7344
CYP450 1A2 substrateNon-inhibitor0.7851
CYP450 2C9 inhibitorNon-inhibitor0.8693
CYP450 2D6 inhibitorInhibitor0.6878
CYP450 2C19 inhibitorNon-inhibitor0.8318
CYP450 3A4 inhibitorNon-inhibitor0.8273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5795
Ames testNon AMES toxic0.8526
CarcinogenicityNon-carcinogens0.9453
BiodegradationNot ready biodegradable0.9962
Rat acute toxicity2.6192 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7839
hERG inhibition (predictor II)Non-inhibitor0.6518
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point199-201 °CPhysProp
water solubility2610 mg/L (at 20 °C)SEIDELL,A (1941)
Predicted Properties
PropertyValueSource
Water Solubility0.835 mg/mLALOGPS
logP1.72ALOGPS
logP1.7ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.78ChemAxon
pKa (Strongest Basic)9.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity89.35 m3·mol-1ChemAxon
Polarizability34.17 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjorneboe A, Christophersen AS, Bodd E, Morland J: Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20. [PubMed:7654478 ]
  2. Xu BQ, Aasmundstad TA, Lillekjendlie B, Bjorneboe A, Christophersen AS, Morland J: Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model. Pharmacol Toxicol. 1997 Apr;80(4):171-81. [PubMed:9140136 ]
External Links
ATC CodesR05DA01S01XA06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Ethylmorphine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Ethylmorphine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Ethylmorphine can be decreased when combined with Abiraterone.
AcepromazineAcepromazine may increase the hypotensive activities of Ethylmorphine.
AcepromazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ethylmorphine.
adipiplonThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethylmorphine.
AlimemazineAlimemazine may increase the hypotensive activities of Ethylmorphine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethylmorphine.
AlvimopanThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amiloride.
AmiodaroneThe metabolism of Ethylmorphine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Ethylmorphine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethylmorphine.
AmoxapineEthylmorphine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethylmorphine.
AmperozideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Ethylmorphine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Ethylmorphine.
AprepitantThe serum concentration of Ethylmorphine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethylmorphine.
ArtemetherThe metabolism of Ethylmorphine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Asenapine.
AtazanavirThe metabolism of Ethylmorphine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Ethylmorphine can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ethylmorphine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Ethylmorphine.
AzaperoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Azaperone.
AzelastineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethylmorphine.
AzosemideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Ethylmorphine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ethylmorphine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethylmorphine.
BenzphetamineBenzphetamine may increase the analgesic activities of Ethylmorphine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Benzyl alcohol.
BetaxololThe metabolism of Ethylmorphine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Ethylmorphine can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Ethylmorphine.
BoceprevirThe metabolism of Ethylmorphine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Ethylmorphine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ethylmorphine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
BrimonidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethylmorphine.
BuprenorphineBuprenorphine may decrease the analgesic activities of Ethylmorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Buprenorphine.
BupropionThe metabolism of Ethylmorphine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethylmorphine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethylmorphine.
ButacaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethylmorphine.
ButorphanolButorphanol may decrease the analgesic activities of Ethylmorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethylmorphine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carisoprodol.
CelecoxibThe metabolism of Ethylmorphine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Ethylmorphine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethylmorphine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethylmorphine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethylmorphine.
ChloroquineThe metabolism of Ethylmorphine can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ethylmorphine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Ethylmorphine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Ethylmorphine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethylmorphine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Ethylmorphine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Ethylmorphine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Ethylmorphine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethylmorphine.
CitalopramEthylmorphine may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Ethylmorphine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Ethylmorphine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Ethylmorphine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clidinium.
ClobazamThe metabolism of Ethylmorphine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with clomethiazole.
ClomipramineEthylmorphine may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Ethylmorphine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clonidine.
ClopidogrelThe metabolism of Ethylmorphine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethylmorphine.
ClotrimazoleThe metabolism of Ethylmorphine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Ethylmorphine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clozapine.
CobicistatThe serum concentration of Ethylmorphine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethylmorphine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethylmorphine.
ConivaptanThe serum concentration of Ethylmorphine can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Conivaptan.
CrizotinibThe metabolism of Ethylmorphine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethylmorphine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Ethylmorphine.
CyclosporineThe metabolism of Ethylmorphine can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyproheptadine.
DabrafenibThe serum concentration of Ethylmorphine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethylmorphine.
DapoxetineEthylmorphine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Ethylmorphine.
DarunavirThe serum concentration of Ethylmorphine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Ethylmorphine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Ethylmorphine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ethylmorphine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethylmorphine.
DesipramineThe metabolism of Ethylmorphine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ethylmorphine.
DesmopressinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Detomidine.
DexamethasoneThe serum concentration of Ethylmorphine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Ethylmorphine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethylmorphine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Ethylmorphine.
DextromoramideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethylmorphine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethylmorphine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethylmorphine.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ethylmorphine.
DifenoxinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Ethylmorphine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethylmorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydromorphine.
DiltiazemThe metabolism of Ethylmorphine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Ethylmorphine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethylmorphine.
DoramectinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Doxepin.
DoxorubicinThe metabolism of Ethylmorphine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Ethylmorphine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
DoxylamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
DronedaroneThe metabolism of Ethylmorphine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethylmorphine.
DrospirenoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Drotebanol.
DuloxetineThe metabolism of Ethylmorphine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine.
EcgonineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Ethylmorphine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Efonidipine.
EliglustatThe metabolism of Ethylmorphine can be decreased when combined with Eliglustat.
EluxadolineEthylmorphine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethylmorphine.
EntacaponeThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Entacapone.
EnzalutamideThe serum concentration of Ethylmorphine can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Eplerenone.
ErythromycinThe metabolism of Ethylmorphine can be decreased when combined with Erythromycin.
EscitalopramEthylmorphine may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ethylmorphine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethylmorphine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethylmorphine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etacrynic acid.
EthanolEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ethylmorphine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethylmorphine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Ethylmorphine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl loflazepate.
EtidocaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethylmorphine.
EtoperidoneEthylmorphine may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etorphine.
EtravirineThe serum concentration of Ethylmorphine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethylmorphine.
FenfluramineEthylmorphine may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethylmorphine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Ethylmorphine.
FexofenadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flibanserin.
FluconazoleThe metabolism of Ethylmorphine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flunitrazepam.
FluoxetineEthylmorphine may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Ethylmorphine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethylmorphine.
FluphenazineFluphenazine may increase the hypotensive activities of Ethylmorphine.
FluphenazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethylmorphine.
FluspirileneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluticasone Propionate.
FluvoxamineEthylmorphine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Ethylmorphine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Ethylmorphine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ethylmorphine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Furosemide.
Fusidic AcidThe serum concentration of Ethylmorphine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethylmorphine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Ethylmorphine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethylmorphine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethylmorphine.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Ethylmorphine.
GuanfacineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethylmorphine.
HaloperidolThe metabolism of Ethylmorphine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethylmorphine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethylmorphine.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Ethylmorphine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethylmorphine.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Ethylmorphine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethylmorphine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethylmorphine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Ethylmorphine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
HydroxyzineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ethylmorphine.
IdelalisibThe serum concentration of Ethylmorphine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Iloperidone.
ImatinibThe metabolism of Ethylmorphine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Ethylmorphine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Imipramine.
IndalpineEthylmorphine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Indapamide.
IndinavirThe metabolism of Ethylmorphine can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethylmorphine.
IsavuconazoniumThe metabolism of Ethylmorphine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethylmorphine.
IsoniazidThe metabolism of Ethylmorphine can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Isosorbide.
IsradipineThe metabolism of Ethylmorphine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Ethylmorphine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Ethylmorphine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethylmorphine.
KetazolamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketobemidone.
KetoconazoleThe metabolism of Ethylmorphine can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Ethylmorphine is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethylmorphine.
LevocabastineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethylmorphine.
LevomilnacipranEthylmorphine may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethylmorphine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethylmorphine.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Ethylmorphine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethylmorphine.
LofentanilThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lofentanil.
LopinavirThe metabolism of Ethylmorphine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethylmorphine.
LorcaserinThe metabolism of Ethylmorphine can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Ethylmorphine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethylmorphine.
Lu AA21004Ethylmorphine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Ethylmorphine.
LuliconazoleThe serum concentration of Ethylmorphine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ethylmorphine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Ethylmorphine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ethylmorphine.
MeclizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethylmorphine.
MelperoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Ethylmorphine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethylmorphine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethylmorphine.
MersalylThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Ethylmorphine.
MesoridazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metaxalone.
MethadoneThe metabolism of Ethylmorphine can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethylmorphine.
MethamphetamineMethamphetamine may increase the analgesic activities of Ethylmorphine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Ethylmorphine.
MethapyrileneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethylmorphine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Ethylmorphine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethylmorphine.
MethsuximideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Ethylmorphine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethylmorphine.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Ethylmorphine.
MetolazoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metolazone.
MetoprololThe metabolism of Ethylmorphine can be decreased when combined with Metoprolol.
MetyrosineEthylmorphine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethylmorphine.
MifepristoneThe metabolism of Ethylmorphine can be decreased when combined with Mifepristone.
MilnacipranEthylmorphine may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
MirabegronThe metabolism of Ethylmorphine can be decreased when combined with Mirabegron.
MirtazapineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethylmorphine.
MitotaneThe serum concentration of Ethylmorphine can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Ethylmorphine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Ethylmorphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethylmorphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Ethylmorphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
NabiloneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nabilone.
NafcillinThe serum concentration of Ethylmorphine can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Ethylmorphine.
NalbuphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Ethylmorphine can be decreased when used in combination with Naltrexone.
NefazodoneThe metabolism of Ethylmorphine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Ethylmorphine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Ethylmorphine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ethylmorphine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Ethylmorphine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Ethylmorphine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Ethylmorphine.
OlanzapineEthylmorphine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethylmorphine.
OlaparibThe metabolism of Ethylmorphine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethylmorphine.
OpiumThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Opium.
OrphenadrineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethylmorphine.
OsanetantThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Osanetant.
OsimertinibThe serum concentration of Ethylmorphine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethylmorphine.
OxprenololThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethylmorphine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ethylmorphine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethylmorphine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethylmorphine.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ethylmorphine.
PalbociclibThe serum concentration of Ethylmorphine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethylmorphine.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Ethylmorphine.
PanobinostatThe metabolism of Ethylmorphine can be decreased when combined with Panobinostat.
ParaldehydeEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ethylmorphine.
ParoxetineEthylmorphine may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Ethylmorphine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Ethylmorphine can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.
PentazocinePentazocine may decrease the analgesic activities of Ethylmorphine.
PentazocineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethylmorphine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Ethylmorphine.
PerampanelThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Ethylmorphine.
PerphenazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethylmorphine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethylmorphine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Ethylmorphine.
PhenytoinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethylmorphine.
PipamperoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ethylmorphine.
PipotiazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Ethylmorphine.
PiretanideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pomalidomide.
PosaconazoleThe metabolism of Ethylmorphine can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium Citrate.
PramipexoleEthylmorphine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethylmorphine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethylmorphine.
PrimidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethylmorphine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Ethylmorphine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Ethylmorphine.
PromazinePromazine may increase the hypotensive activities of Ethylmorphine.
PromazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Ethylmorphine.
PromethazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Ethylmorphine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethylmorphine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethylmorphine.
PropoxycaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Ethylmorphine is combined with PSD502.
QuazepamThe serum concentration of Ethylmorphine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethylmorphine.
QuinethazoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Ethylmorphine.
QuinineThe metabolism of Ethylmorphine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ramelteon.
RamosetronEthylmorphine may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Ethylmorphine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethylmorphine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethylmorphine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethylmorphine.
RifabutinThe metabolism of Ethylmorphine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ethylmorphine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ethylmorphine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethylmorphine.
RitonavirThe metabolism of Ethylmorphine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Ethylmorphine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Romifidine.
RopiniroleEthylmorphine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Ethylmorphine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethylmorphine.
RotigotineEthylmorphine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethylmorphine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Ethylmorphine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethylmorphine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Ethylmorphine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethylmorphine.
SertindoleThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Sertindole.
SertralineEthylmorphine may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Ethylmorphine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethylmorphine.
SildenafilThe metabolism of Ethylmorphine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Ethylmorphine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ethylmorphine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Ethylmorphine.
SorafenibThe metabolism of Ethylmorphine can be decreased when combined with Sorafenib.
SpironolactoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Spironolactone.
St. John's WortThe serum concentration of Ethylmorphine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Ethylmorphine.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.
SulfisoxazoleThe metabolism of Ethylmorphine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethylmorphine.
SuvorexantThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tasimelteon.
TelaprevirThe metabolism of Ethylmorphine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Ethylmorphine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethylmorphine.
TerbinafineThe metabolism of Ethylmorphine can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrodotoxin.
ThalidomideEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethylmorphine.
TheobromineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethylmorphine.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Ethylmorphine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethylmorphine.
ThioridazineThioridazine may increase the hypotensive activities of Ethylmorphine.
ThioridazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Thioridazine.
ThiotepaThe metabolism of Ethylmorphine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiagabine.
TiclopidineThe metabolism of Ethylmorphine can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Ethylmorphine.
TipranavirThe metabolism of Ethylmorphine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tizanidine.
TocilizumabThe serum concentration of Ethylmorphine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Ethylmorphine.
TolvaptanThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethylmorphine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Ethylmorphine can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tranylcypromine.
TrazodoneEthylmorphine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethylmorphine.
TriamtereneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethylmorphine.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Ethylmorphine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Ethylmorphine.
TriflupromazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ethylmorphine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Ethylmorphine.
TrimipramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Ethylmorphine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Ethylmorphine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Ethylmorphine.
UlaritideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Ethylmorphine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethylmorphine.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ethylmorphine.
VenlafaxineThe metabolism of Ethylmorphine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Ethylmorphine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Vigabatrin.
VilazodoneEthylmorphine may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Ethylmorphine can be decreased when combined with Voriconazole.
VortioxetineEthylmorphine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ethylmorphine.
XylazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethylmorphine.
ZiconotideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ziconotide.
ZimelidineEthylmorphine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Ethylmorphine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethylmorphine.
ZonisamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethylmorphine.
ZotepineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [PubMed:16530171 ]
  2. Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23. [PubMed:16580639 ]
  3. Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31. [PubMed:16580848 ]
  4. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8. [PubMed:16682505 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjorneboe A, Christophersen AS, Bodd E, Morland J: Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20. [PubMed:7654478 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name:
POR
Uniprot ID:
P16435
Molecular Weight:
76689.12 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23